

HIV Medicine: Letter

Title

Central obesity and non-alcoholic fatty liver disease in people living with HIV: a case for targeted screening?

Short title

NAFLD in HIV

Authors

C Dewar¹, QM Anstee^{2,3}, DA Price¹, BAI Payne^{1,4}

Affiliations

¹Department of Infection and Tropical Medicine, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK; ²Institute of Cellular Medicine, Newcastle University, UK; ³Liver Unit, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK; ⁴Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, UK.

Corresponding author

Dr Brendan Payne

Wellcome Centre for Mitochondrial Research, 4th Floor Cookson Building, Medical School, Framlington Place, Newcastle-upon-Tyne, NE2 4HH.

T: +44 (0)191 208 5295

E: Brendan.Payne@ncl.ac.uk

Keywords

HIV; Non-alcoholic Fatty Liver Disease; Obesity; Insulin Resistance

Main text

Sir,

Non-alcoholic fatty liver disease (NAFLD) is common in people living with HIV (PLWH) (1). A recent update to European guidance suggests screening for NAFLD in PLWH who also have metabolic syndrome (MetS) (2). Equivalent UK guidance does not yet exist. We therefore aimed to pilot a pragmatic approach to NAFLD, using data routinely collected in a UK HIV clinic setting.

Consecutive adult PLWH attending for outpatient care were reviewed, and those with recurrently abnormal liver function (defined here as ALT >ULN on ≥ 2 occasions in last 13 months) were identified for further evaluation. At next planned visit we assessed central obesity (CO, by waist circumference (WC), per WHO cut-offs (3)) and insulin resistance (IR, defined as type 2 diabetes mellitus and/or elevated HbA_{1c} >42mmol/mol). Where a presumptive diagnosis of NAFLD was made, staging was performed using the NAFLD Fibrosis Score (NAFLD-FS) (4).

544 consecutive patients were evaluated. 100 (18%) had recurrently abnormal ALT. Of these 46 were excluded owing to viral hepatitis co-infection, alcohol excess, or other liver disease, and 10 did not attend for imaging. Of the remaining 44 patients (83% male, mean age 49.2 years, mean duration of diagnosed HIV infection 9.5 years, 91% ART treated), CO was present in 74%. By body mass index,

25% were overweight (BMI 25-29.9) and 37% obese (BMI ≥ 30). Of note, 22% of subjects with CO had normal BMI. 23% had IR, and 14% MetS, all of whom had coexisting CO.

After other causes were excluded, NAFLD was the commonest cause of liver disease, with a prevalence of 55% (representing 24% of all those with recurrently elevated ALT). A further 18% had possible NAFLD (CO/IR with no fat on USS). 88% of NAFLD cases were previously undiagnosed. Almost all patients with NAFLD had CO (sensitivity 94%, specificity 50%). BMI-defined obesity was less sensitive (Sn 80%, Sp 47%), and most did not have overt IR (Sn 29%, Sp 88%) or MetS. There was no association between presence of NAFLD and current or nadir CD4 count, duration of HIV infection, or duration or class of ART. Of subjects with NAFLD, 74% had low, 21% indeterminate, and 5% high fibrosis risk.

The prevalence of recurrently elevated ALT in a typical HIV cohort was high. NAFLD was the commonest cause of liver disease, and a large majority of cases were previously undiagnosed. As a pragmatic study based on current UK monitoring practice, we considered only those PLWH with elevated ALT. As such, we will have underestimated the true prevalence of NAFLD. WC will identify almost all PLWH with NAFLD, but the EACS approach of screening only those with MetS, whilst highly specific, appears to be insufficiently sensitive. It is noteworthy that, in the contemporary HIV clinic, 'lean NAFLD' is uncommon.

We therefore recommend implementation of routine WC measurement in UK clinical care (this will also enhance cardiovascular risk stratification), with targeting of NAFLD screening to those PLWH with CO. Future work should compare the Sn/Sp of this approach in the presence or absence of elevated ALT.

(500w)

Acknowledgements

The authors acknowledge the support of the NIHR Newcastle Biomedical Research Centre. BP is funded by Wellcome (109975/Z/15/Z).

Insert

Figure 1. Suggested approach to NAFLD in PLWH. CO, central obesity; IR, insulin resistance; MetS, metabolic syndrome; USS, ultrasound scan; NAFLD-FS, NAFLD fibrosis score; TE, transient elastography. Adapted from Dyson *et al.* (5)

References

1. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. *AIDS (London, England)*. 2017;31(11):1621-32.
2. Society EAC. Guidelines 2017 [updated 01/10/2017. 9.0:[Available from: <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>.
3. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. 2011.
4. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45(4):846-54.
5. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. *Frontline Gastroenterol*. 2014;5(3):211-8.

